Newsroom

LATEST PUBLICATIONS

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

2025-11-24T09:51:38-08:00November 24th, 2025|

QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib

2025-10-28T11:29:07-07:00September 3rd, 2025|

A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML

2025-07-29T15:39:42-07:00July 29th, 2025|

Performance Comparison of Illumina^® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack^® Assays

2025-09-18T16:16:23-07:00May 27th, 2025|

From prognostication to precision in acute myeloid leukemia

2025-05-08T16:47:49-07:00May 8th, 2025|

Invivoscribe Announces the PrepQuant^TM System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows

2026-04-15T10:35:21-07:00April 15th, 2026|

Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification

2026-03-25T23:07:06-07:00March 25th, 2026|

Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

2026-02-05T14:09:13-08:00February 4th, 2026|

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

2026-03-09T18:04:28-07:00July 7th, 2025|

LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials

2026-03-09T18:40:09-07:00June 17th, 2025|

115th The Annual meeting of the Japanese Society of Pathology

Apr 16 – 18, 2026
Sapporo, Japan
Attending

AACR

Apr 17–22, 2026
San Diego, CA
Exhibiting
Visit Conference Website

BSH 2026

Apr 19-21, 2026
Liverpool, UK
Attending
Visit Conference Website

2nd EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

Apr 30–May 2, 2026
Ljubljana, Slovenia
Attending
Visit Conference Website

TRI-CON 2026

May 4-5, 2026
San Francisco, CA
Attending
Visit Conference Website

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

115th The Annual meeting of the Japanese Society of Pathology

AACR

BSH 2026

2nd EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

TRI-CON 2026

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.